Limits...
Safety and Visual Outcome of Visian Toric ICL Implantation after Corneal Collagen Cross-Linking in Keratoconus: Up to 2 Years of Follow-Up.

Antonios R, Dirani A, Fadlallah A, Chelala E, Hamade A, Cherfane C, Jarade E - J Ophthalmol (2015)

Bottom Line: Mean cylinder power and mean spherical equivalent (SE) also decreased significantly after ICL implantation.A small hyperopic shift in SE (+0.25 D) was observed at 2 years that did not alter visual outcomes.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

ABSTRACT
Purpose. To evaluate the long-term safety and clinical outcome of phakic Visian toric implantable collamer lens (ICL) insertion after corneal collagen cross-linking (CXL) in progressive keratoconus. Methods. This was a retrospective study of 30 eyes (19 patients), with progressive keratoconus, who underwent sequential CXL followed by Visian toric ICL implantation after 6 months. Results. At baseline, 6 eyes had stage I, 14 eyes stage II, and 10 eyes stage III keratoconus graded by Amsler-Krumeich classification. At 6 months after CXL, only K (steep) and K (max) decreased significantly from baseline, with no change in visual acuity or refraction. Flattening in keratometric readings was stable thereafter. There was significant improvement in mean uncorrected distance visual acuity (1.57 ± 0.56 to 0.17 ± 0.06 logMAR, P < 0.001) and mean corrected distance visual acuity (0.17 ± 0.08 to 0.11 ± 0.05 logMAR, P < 0.001) at 12 months after ICL implantation that was maintained at the 2-year follow-up. Mean cylinder power and mean spherical equivalent (SE) also decreased significantly after ICL implantation. A small hyperopic shift in SE (+0.25 D) was observed at 2 years that did not alter visual outcomes. Conclusions. Visian toric ICL implantation following CXL is an effective option for improving visual acuity in patients with keratoconus up to 2 years.

No MeSH data available.


Related in: MedlinePlus

Change in corrected distance visual acuity (CDVA) following toric implantable collamer lens implantation (ICL).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4383407&req=5

fig1: Change in corrected distance visual acuity (CDVA) following toric implantable collamer lens implantation (ICL).

Mentions: According to Table 1, both UDVA and CDVA values at 6 months after CXL did not differ from baseline (P = 1.000 and 0.231, resp.). At 6 months after ICL implantation, there was significant improvement in mean UDVA from 1.57 logMAR to 0.17 logMAR (P < 0.001) and mild improvement in CDVA from 0.17 logMAR to 0.11 logMAR (P < 0.001). Both CDVA and UDVA remained stable thereafter up to 24 months (Tables 1 and 2). No eye lost 2 or more lines in CDVA in the study (Figure 1). At 12 months, 43% (13 of 30) of eyes gained ≥1 line in CDVA, and in the smaller subset of eyes with 24 months follow-up 60% of eyes gained ≥1 line in CDVA. Overall, 60% (18 of 30) and 50% (5 of 10) of eyes had UDVA of 20/30 or better 12 months and 24 months after ICL implantation, respectively.


Safety and Visual Outcome of Visian Toric ICL Implantation after Corneal Collagen Cross-Linking in Keratoconus: Up to 2 Years of Follow-Up.

Antonios R, Dirani A, Fadlallah A, Chelala E, Hamade A, Cherfane C, Jarade E - J Ophthalmol (2015)

Change in corrected distance visual acuity (CDVA) following toric implantable collamer lens implantation (ICL).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4383407&req=5

fig1: Change in corrected distance visual acuity (CDVA) following toric implantable collamer lens implantation (ICL).
Mentions: According to Table 1, both UDVA and CDVA values at 6 months after CXL did not differ from baseline (P = 1.000 and 0.231, resp.). At 6 months after ICL implantation, there was significant improvement in mean UDVA from 1.57 logMAR to 0.17 logMAR (P < 0.001) and mild improvement in CDVA from 0.17 logMAR to 0.11 logMAR (P < 0.001). Both CDVA and UDVA remained stable thereafter up to 24 months (Tables 1 and 2). No eye lost 2 or more lines in CDVA in the study (Figure 1). At 12 months, 43% (13 of 30) of eyes gained ≥1 line in CDVA, and in the smaller subset of eyes with 24 months follow-up 60% of eyes gained ≥1 line in CDVA. Overall, 60% (18 of 30) and 50% (5 of 10) of eyes had UDVA of 20/30 or better 12 months and 24 months after ICL implantation, respectively.

Bottom Line: Mean cylinder power and mean spherical equivalent (SE) also decreased significantly after ICL implantation.A small hyperopic shift in SE (+0.25 D) was observed at 2 years that did not alter visual outcomes.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

ABSTRACT
Purpose. To evaluate the long-term safety and clinical outcome of phakic Visian toric implantable collamer lens (ICL) insertion after corneal collagen cross-linking (CXL) in progressive keratoconus. Methods. This was a retrospective study of 30 eyes (19 patients), with progressive keratoconus, who underwent sequential CXL followed by Visian toric ICL implantation after 6 months. Results. At baseline, 6 eyes had stage I, 14 eyes stage II, and 10 eyes stage III keratoconus graded by Amsler-Krumeich classification. At 6 months after CXL, only K (steep) and K (max) decreased significantly from baseline, with no change in visual acuity or refraction. Flattening in keratometric readings was stable thereafter. There was significant improvement in mean uncorrected distance visual acuity (1.57 ± 0.56 to 0.17 ± 0.06 logMAR, P < 0.001) and mean corrected distance visual acuity (0.17 ± 0.08 to 0.11 ± 0.05 logMAR, P < 0.001) at 12 months after ICL implantation that was maintained at the 2-year follow-up. Mean cylinder power and mean spherical equivalent (SE) also decreased significantly after ICL implantation. A small hyperopic shift in SE (+0.25 D) was observed at 2 years that did not alter visual outcomes. Conclusions. Visian toric ICL implantation following CXL is an effective option for improving visual acuity in patients with keratoconus up to 2 years.

No MeSH data available.


Related in: MedlinePlus